SGLT1: A Potential Drug Target for Cardiovascular Disease
Drug Design, Development and Therapy · 2023-07 · Volume 17 · 2011-2023
DOI: 10.2147/dddt.s418321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023-07. Verfasst von Mengnan Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
ORCID-Profile: Na Li
Zitieren
APA
Zhao, M., Li, N., & Zhou, H. (2023). SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Design, Development and Therapy, Volume 17, 2011-2023. https://doi.org/10.2147/dddt.s418321
Vancouver
Zhao M, Li N, Zhou H. SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Design, Development and Therapy. 2023;Volume 17:2011-2023. doi:10.2147/dddt.s418321
BibTeX
@article{Zhao2023,
author = {Zhao, Mengnan and Li, Na and Zhou, Hong},
title = {SGLT1: A Potential Drug Target for Cardiovascular Disease},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {2011--2023},
doi = {10.2147/dddt.s418321}
}
EUVIMED